About Index Trending news
Lists
Pricing
Agios Pharmaceuticals

Agios Pharmaceuticals

Agios Pharmaceuticals

Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan gen

Elsewhere

Alexa global traffic share

Latest funding
Venture capital (Series C)
$78,000,000
Employees

Team size

50+
Locations
HQ
Xconomy

Celgene Plots Speedy FDA Filing for Agios Blood Cancer Drug

Health Science
The Motley Fool

This Is Why Agios Pharmaceuticals' Stock Rose 14.3% in May

The Motley Fool

Why Agios Pharmaceuticals Inc. Presented Lower Today

Xconomy

Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance

Health
The Motley Fool

A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April

Stock markets Health
The Motley Fool

The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January

The Motley Fool

Expectations for Perfection Haunt Agios Pharmaceuticals Inc. in November --

$78,000,000 Venture capital (Series C)
FinSMEs

Agios Pharmaceuticals Raises $78M in Series C Financing